Rx Road Map: Amivantamab (Rybrevant) Plus Lazertinib (Lazcluze)
APPs provide an in-depth look at amivantamab plus lazertinib for the treatment of patients with locally advanced or metastatic non–small cell lung cancer.
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
Safety Management With Amivantamab Plus Lazertinib in NSCLC
